Or call 888-224-2480 for fastest service.

You can save an extra 10% off the current rate by using code D10-999-JDS22.

This June, join the “who’s who” of the biosimilars and innovator biologics industries as they gather in Boston for ACI’s 13th Annual Summit on Biosimilars & Innovator Biologics.

2022 CO-CHAIRS

Biologics have become the fastest-growing class of therapeutic compounds. They have provided innovative treatment alternatives for people who suffer from some of the most serious medical conditions known to man. The incorporation of biosimilar products into the U.S. marketplace was designed to improve patient access and decrease healthcare costs. While much has evolved since the enactment of the BPCIA, the traditional barriers remain.

The next decade will see more litigation in this sphere. Further, and to an increasing extent, IPR proceedings challenging patents protecting biologic medicines, including IPRs filed before any action was taken under the BPCIA. Finally, the future will usher in considerable changes growing the scope of products that are regulated and litigated under the BPCIA.

Now, more than ever, strategies to overcome these barriers are essential to improve the understanding of biosimilar products in the United States. We cordially invite you to explore the contours of the rapidly changing landscape for biosimilars and innovator biologics with the industry stakeholders, including in-house counsel from branded and biosimilars companies, senior government officials from FDA, USPTO and the Judiciary, as well as regulatory and patent attorneys from around the country.

EXCLUSIVE INSIGHTS FROM

Save an extra 10% off the conference by using code D10-999-JDS22.

*Discount is valid for new registrations only and it’s not applicable for workshops.